全文获取类型
收费全文 | 239篇 |
免费 | 7篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 1篇 |
临床医学 | 108篇 |
内科学 | 70篇 |
皮肤病学 | 6篇 |
神经病学 | 2篇 |
特种医学 | 6篇 |
外科学 | 6篇 |
综合类 | 5篇 |
预防医学 | 14篇 |
药学 | 8篇 |
肿瘤学 | 2篇 |
出版年
2019年 | 1篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 5篇 |
2012年 | 24篇 |
2011年 | 23篇 |
2010年 | 14篇 |
2009年 | 20篇 |
2008年 | 11篇 |
2007年 | 20篇 |
2006年 | 24篇 |
2005年 | 11篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 8篇 |
1998年 | 9篇 |
1997年 | 4篇 |
1996年 | 5篇 |
1995年 | 10篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1984年 | 2篇 |
1981年 | 1篇 |
1978年 | 2篇 |
1959年 | 4篇 |
1947年 | 2篇 |
1946年 | 1篇 |
1945年 | 1篇 |
排序方式: 共有250条查询结果,搜索用时 15 毫秒
81.
HONG GEE SIM SIDNEY KAM HUNG YIP WEBER KAM ON LAU YEH HONG TAN MICHAEL YUET CHEN WONG CHRISTOPHER WAI SAM CHENG 《International journal of urology》2006,13(5):560-564
AIM: We assessed the team approach in reducing the learning curve during our 2-year experience transiting from open to robot-assisted laparoscopic radical prostatectomy (rLRP). METHODS: A team of three urologists progressed through assistant phase to console phase to obtain competency in robotic prostatectomy. One hundred patients underwent rLRP by this team using the da Vinci robotic surgical system from 1 February 2003 to 15 May 2005. RESULTS: The immediate perioperative outcome was divided into three corresponding time frames and the results demonstrated gradual improvement in outcome parameters. The mean set-up time and dissection time were 24+/-14 min and 182+/-52 min, respectively. The mean perioperative blood loss was 272+/-240 mL, and 7% of patients (n=7) required blood transfusion. The mean duration of bladder catheterization was 8.4+/-4.1 days, and mean hospital stay was 2.9+/-1.6 days. There was no perioperative mortality or conversion to open radical prostatectomy. Major complications (4%) included urethrovesical leak requiring re-operation, postoperative cerebrovascular accident, and transient ureteric obstruction. Minor complications (7%) included minor urethrovesical leak, bladder neck stenosis, and urinary tract infection. Mean follow up was 6.6+/-5.0 months. Pathological assessment showed pT2 disease in 55% and pT3 in 45% of specimens. CONCLUSIONS: A team-based approach to robot-assisted LRP helped to reduce the learning curve of the procedure for individual surgeons and continued to show significantly lower perioperative blood loss, transfusion requirements and postoperative pain compared to open radical retropubic prostatectomy. 相似文献
82.
C. I. JONES S. F. GARNER†‡ W. ANGENENT§ A. BERNARD§ C. BERZUINI¶ P. BURNS† R. W. FARNDALE†† J. HOGWOOD‡‡ A. RANKIN†‡ J. C. STEPHENS† B. D. TOM¶ J. WALTON‡ F. DUDBRIDGE¶ W. H. OUWEHAND†‡ A. H. GOODALL ON BEHALF OF THE BLOODOMICS CONSORTIUM 《Journal of thrombosis and haemostasis》2007,5(8):1756-1765
BACKGROUND: Evidence suggests the wide variation in platelet response within the population is genetically controlled. Unraveling the complex relationship between sequence variation and platelet phenotype requires accurate and reproducible measurement of platelet response. OBJECTIVE: To develop a methodology suitable for measuring signaling pathway-specific platelet phenotype, to use this to measure platelet response in a large cohort, and to demonstrate the effect size of sequence variation in a relevant model gene. METHODS: Three established platelet assays were evaluated: mobilization of [Ca(2+)](i), aggregometry and flow cytometry, each in response to adenosine 5'-diphosphate (ADP) or the glycoprotein (GP) VI-specific crosslinked collagen-related peptide (CRP). Flow cytometric measurement of fibrinogen binding and P-selectin expression in response to a single, intermediate dose of each agonist gave the best combination of reproducibility and inter-individual variability and was used to measure the platelet response in 506 healthy volunteers. Pathway specificity was ensured by blocking the main subsidiary signaling pathways. RESULTS: Individuals were identified who were hypo- or hyper-responders for both pathways, or who had differential responses to the two agonists, or between outcomes. 89 individuals, retested three months later using the same methodology, showed high concordance between the two visits in all four assays (r(2) = 0.872, 0.868, 0.766 and 0.549); all subjects retaining their phenotype at recall. The effect of sequence variation at the GP6 locus accounted for approximately 35% of the variation in the CRP-XL response. CONCLUSION: Genotyping-phenotype association studies in a well-characterized, large cohort provides a powerful strategy to measure the effect of sequence variation in genes regulating the platelet response. 相似文献
83.
84.
85.
S. REVEL‐VILK L. R. BRANDÃO J. JOURNEYCAKE A. GOLDENBERG P. MONAGLE A. SHARATHKUMAR A. K. C. CHAN ON BEHALF OF THE PERINATAL PAEDIATRIC HAEMOSTASIS SUBCOMMITTEE OF THE SCIENTIFIC STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS HAEMOSTASIS 《Journal of thrombosis and haemostasis》2012,10(10):2182-2185
86.
87.
88.
89.
B. M. FELDMAN‡§¶ M. PAI G. E. RIVARD†† S. ISRAELS‡‡ M.-C. POON§§ C. DEMERS¶¶ S. ROBINSON K.-H. LUKE††† J. K. M. WU‡‡‡ K. GILL§§§ D. LILLICRAP¶¶¶ P. BABYN M. MCLIMONT†‡ V. S. BLANCHETTE†§ ON BEHALF OF THE ASSOCIATION OF HEMOPHILIA CLINIC DIRECTORS OF CANADA PROPHYLAXIS STUDY GROUP 《Journal of thrombosis and haemostasis》2006,4(6):1228-1236
BACKGROUND: Prophylactic treatment for severe hemophilia A is likely to be more effective than treatment when bleeding occurs, however, prophylaxis is costly. We studied an inception cohort of 25 boys using a tailored prophylaxis approach to see if clotting factor use could be reduced with acceptable outcomes. METHODS: Ten Canadian centers enrolled subjects in this 5-year study. Children were followed every 3 months at a comprehensive care hemophilia clinic. They were initially treated with once-weekly clotting factor; the frequency was escalated in a stepwise fashion if unacceptable bleeding occurred. Bleeding frequency, target joint development, physiotherapy and radiographic outcomes, as well as resource utilization, were determined prospectively. RESULTS: The median follow-up time was 4.1 years (total 96.9 person-years). The median time to escalate to twice-weekly therapy was 3.42 years (lower 95% confidence limit 2.05 years). Nine subjects developed target joints at a rate of 0.09 per person-year. There was an average of 1.2 joint bleeds per person-year. The cohort consumed on average 3656 IU kg(-1)year(-1) of factor (F) VIII. Ten subjects required central venous catheters (three while on study); no complications of these devices were seen. One subject developed a transient FVIII inhibitor. End-of-study joint examination scores--both clinically and radiographically--were normal or near-normal. CONCLUSIONS: Most boys with severe hemophilia A will probably have little bleeding and good joint function with tailored prophylaxis, while infusing less FVIII than usually required for traditional prophylaxis. 相似文献
90.
U. MARTINOWITZ M. MICHAELSON† ON BEHALF OF THE ISRAELI MULTIDISCIPLINARY rFVIIa TASK FORCE 《Journal of thrombosis and haemostasis》2005,3(4):640-648
BACKGROUND: Recombinant activated factor VII (rFVIIa) has been approved by the U.S. Food and Drug Administration (FDA) for almost a decade for hemophilic patients with inhibitors. Its off-label use as a hemostatic agent in massive bleeding caused by a wide array of clinical scenarios is rapidly expanding. While evidence-based guidelines exist for rFVIIa treatment in hemophilia, none are available for its off-label use. Objectives: The aim of this study is to develop expert recommendations for the use of rFVIIa in patients suffering from uncontrolled bleeding (with special emphasis on trauma) until randomized, controlled trials allow for the introduction of more established evidence-based guidelines. METHODS: A multidisciplinary task force comprising representatives of the relevant National Medical Associations, experts from the Medical Corps of the Army, Ministry of Health and the Israel National Trauma Advisory Board was established in Israel. Recommendations were construed based on the analysis of the first 36 multi-trauma patients accumulated in the prospective national registry of the use of rFVIIa in trauma, and an extensive literature search consisting of published and prepublished controlled animal trials, case reports and series. The final consensus guidelines, together with the data of the first 36 trauma patients treated in Israel, are presented in this article. RESULTS: Results of the first 36 trauma patients: The prolonged clotting assays [prothrombin time (PT) and partial thromboplastin time (PTT)] shortened significantly within minutes following administration of rFVIIa. Cessation of bleeding was achieved in 26 of 36 (72%) patients. Acidosis diminished the hemostatic effect of the drug, while hypothermia did not affect it. The survival rate of 61% (22/36) seems to be favorable compared with published series of similar, or less severe, trauma patients (range 30%-57%). CONCLUSIONS: As a result of the lack of controlled trials, our guidelines should be considered as suggestive rather than conclusive. However, they provide a valuable tool for physicians using rFVIIa for the expanding off-label clinical uses. 相似文献